Synergy Pharmaceuticals
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
420 Lexington Ave Rm 2500, New York City...Phone Number
(212) 297-0020Website
www.synergypharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New...Explore more
Synergy Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Synergy Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Synergy Pharmaceuticals launches new products
Check if Synergy Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Synergy Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Synergy Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Synergy Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Synergy Pharmaceuticals recently announced quarterly report
Funding: Get notified immidiatlly once Synergy Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at Synergy Pharmaceuticals
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Synergy Pharmaceuticals
Compare insights from companies similar to Synergy Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Synergy Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Synergy Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Synergy Pharmaceuticals.
Synergy Pharmaceuticals financials insights
Gather financial insights about Synergy Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Debt
$300M
Synergy Pharmaceuticals Tech Stack
A closer look at the technologies used by Synergy Pharmaceuticals
Synergy Pharmaceuticals News & Media
SYNERGY INVESTORS APRIL 12th DEADLINE ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc.; Encourages Investors With Losses In Excess of $100K to Contact the Firm – SGYP
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) from September 5, 2017 through October 25, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Synergy investors under the federal securities laws. To join the Synergy class action, go to http://www.rosenlegal.com/cases-register-1545.html or call Phillip KimSynergy Pharmaceuticals Announces Completion of Sale to Bausch Health
NEW YORK, March 6, 2019 /PRNewswire/ -- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) (the "Company" or "Synergy"), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today confirmed that the previously announced sale of...Bausch Health Completes Acquisition Of Certain Assets Of Synergy Pharmaceuticals Inc.
LAVAL, Quebec, March 6, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that the Company has completed the acquisition of certain assets of Synergy Pharmaceuticals Inc. (NASD: SGYP) ("Synergy") for a cash purchase price...Synergy Pharmaceuticals Receives Court Approval for the Sale of Its Assets to Bausch Health
NEW YORK, March 1, 2019 /PRNewswire/ -- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) (the "Company" or "Synergy"), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today confirmed that the previously announced agreement...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Synergy Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel s... Read More
